Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate

Thomas N. Eade, Tahseen Al-Saleem, Eric M. Horwitz, Mark K. Buyyounouski, David Y T Chen, Alan Pollack

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND. Ductal carcinoma of the prostate is a rare variant of prostate cancer that presents most commonly with obstructive urinary symptoms or hematuria. This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy. METHODS. A retrospective review was performed of patients treated between 1980 and 2006 at Fox Chase Cancer Center, Philadelphia, Penn. Six patients were identified with ductal carcinoma. RESULTS. Five of the 6 patients were treated definitively and the sixth patient was treated at recurrence 3 years after a radical prostatectomy. Patient ages ranged from 66-80 years and the initial prostate-specific antigen (iPSA) ranged from 1.69-100.3 ng/mL. Three patients had a mixed acinar and ductal carcinoma, 2 with a Gleason score (GS) of 8 and 1 with a GS of 7. Of the patients treated definitively, 4 had clinical stage T2A-T2C and 1 had clinical stage T1B. Definitive radiotherapy was delivered to the prostate with doses between 72 Gy and 78 Gy. Pelvic lymph nodes were treated in all patients. One patient was treated postradical prostatectomy to the prostate bed to a dose of 60 Gy. Adjuvant androgen deprivation was given in 5 of the patients. Two of the patients died from metastatic disease at 1.4 and 7.1 years after treatment. The remaining 4 patients remain alive between 3.2 and 4.8 years from treatment, with 3 patients biochemically without evidence of disease. No patients have developed a local recurrence. CONCLUSIONS. Ductal carcinoma of the prostate may be treated effectively with external beam radiotherapy. Aggressive management is indicated, even with low-volume metastatic disease.

Original languageEnglish
Pages (from-to)2011-2015
Number of pages5
JournalCancer
Volume109
Issue number10
DOIs
StatePublished - May 15 2007
Externally publishedYes

Fingerprint

Endometrioid Carcinoma
Ductal Carcinoma
Prostate
Radiotherapy
Neoplasm Grading
Prostatectomy
Acinar Cell Carcinoma
Recurrence
Hematuria
Prostate-Specific Antigen

Keywords

  • Ductal carcinoma
  • Prosiate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eade, T. N., Al-Saleem, T., Horwitz, E. M., Buyyounouski, M. K., Chen, D. Y. T., & Pollack, A. (2007). Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer, 109(10), 2011-2015. https://doi.org/10.1002/cncr.22644

Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. / Eade, Thomas N.; Al-Saleem, Tahseen; Horwitz, Eric M.; Buyyounouski, Mark K.; Chen, David Y T; Pollack, Alan.

In: Cancer, Vol. 109, No. 10, 15.05.2007, p. 2011-2015.

Research output: Contribution to journalArticle

Eade, TN, Al-Saleem, T, Horwitz, EM, Buyyounouski, MK, Chen, DYT & Pollack, A 2007, 'Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate', Cancer, vol. 109, no. 10, pp. 2011-2015. https://doi.org/10.1002/cncr.22644
Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DYT, Pollack A. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007 May 15;109(10):2011-2015. https://doi.org/10.1002/cncr.22644
Eade, Thomas N. ; Al-Saleem, Tahseen ; Horwitz, Eric M. ; Buyyounouski, Mark K. ; Chen, David Y T ; Pollack, Alan. / Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. In: Cancer. 2007 ; Vol. 109, No. 10. pp. 2011-2015.
@article{c8ef5d0c0c95401b8e547c87df6af5e9,
title = "Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate",
abstract = "BACKGROUND. Ductal carcinoma of the prostate is a rare variant of prostate cancer that presents most commonly with obstructive urinary symptoms or hematuria. This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy. METHODS. A retrospective review was performed of patients treated between 1980 and 2006 at Fox Chase Cancer Center, Philadelphia, Penn. Six patients were identified with ductal carcinoma. RESULTS. Five of the 6 patients were treated definitively and the sixth patient was treated at recurrence 3 years after a radical prostatectomy. Patient ages ranged from 66-80 years and the initial prostate-specific antigen (iPSA) ranged from 1.69-100.3 ng/mL. Three patients had a mixed acinar and ductal carcinoma, 2 with a Gleason score (GS) of 8 and 1 with a GS of 7. Of the patients treated definitively, 4 had clinical stage T2A-T2C and 1 had clinical stage T1B. Definitive radiotherapy was delivered to the prostate with doses between 72 Gy and 78 Gy. Pelvic lymph nodes were treated in all patients. One patient was treated postradical prostatectomy to the prostate bed to a dose of 60 Gy. Adjuvant androgen deprivation was given in 5 of the patients. Two of the patients died from metastatic disease at 1.4 and 7.1 years after treatment. The remaining 4 patients remain alive between 3.2 and 4.8 years from treatment, with 3 patients biochemically without evidence of disease. No patients have developed a local recurrence. CONCLUSIONS. Ductal carcinoma of the prostate may be treated effectively with external beam radiotherapy. Aggressive management is indicated, even with low-volume metastatic disease.",
keywords = "Ductal carcinoma, Prosiate cancer, Radiotherapy",
author = "Eade, {Thomas N.} and Tahseen Al-Saleem and Horwitz, {Eric M.} and Buyyounouski, {Mark K.} and Chen, {David Y T} and Alan Pollack",
year = "2007",
month = "5",
day = "15",
doi = "10.1002/cncr.22644",
language = "English",
volume = "109",
pages = "2011--2015",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate

AU - Eade, Thomas N.

AU - Al-Saleem, Tahseen

AU - Horwitz, Eric M.

AU - Buyyounouski, Mark K.

AU - Chen, David Y T

AU - Pollack, Alan

PY - 2007/5/15

Y1 - 2007/5/15

N2 - BACKGROUND. Ductal carcinoma of the prostate is a rare variant of prostate cancer that presents most commonly with obstructive urinary symptoms or hematuria. This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy. METHODS. A retrospective review was performed of patients treated between 1980 and 2006 at Fox Chase Cancer Center, Philadelphia, Penn. Six patients were identified with ductal carcinoma. RESULTS. Five of the 6 patients were treated definitively and the sixth patient was treated at recurrence 3 years after a radical prostatectomy. Patient ages ranged from 66-80 years and the initial prostate-specific antigen (iPSA) ranged from 1.69-100.3 ng/mL. Three patients had a mixed acinar and ductal carcinoma, 2 with a Gleason score (GS) of 8 and 1 with a GS of 7. Of the patients treated definitively, 4 had clinical stage T2A-T2C and 1 had clinical stage T1B. Definitive radiotherapy was delivered to the prostate with doses between 72 Gy and 78 Gy. Pelvic lymph nodes were treated in all patients. One patient was treated postradical prostatectomy to the prostate bed to a dose of 60 Gy. Adjuvant androgen deprivation was given in 5 of the patients. Two of the patients died from metastatic disease at 1.4 and 7.1 years after treatment. The remaining 4 patients remain alive between 3.2 and 4.8 years from treatment, with 3 patients biochemically without evidence of disease. No patients have developed a local recurrence. CONCLUSIONS. Ductal carcinoma of the prostate may be treated effectively with external beam radiotherapy. Aggressive management is indicated, even with low-volume metastatic disease.

AB - BACKGROUND. Ductal carcinoma of the prostate is a rare variant of prostate cancer that presents most commonly with obstructive urinary symptoms or hematuria. This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy. METHODS. A retrospective review was performed of patients treated between 1980 and 2006 at Fox Chase Cancer Center, Philadelphia, Penn. Six patients were identified with ductal carcinoma. RESULTS. Five of the 6 patients were treated definitively and the sixth patient was treated at recurrence 3 years after a radical prostatectomy. Patient ages ranged from 66-80 years and the initial prostate-specific antigen (iPSA) ranged from 1.69-100.3 ng/mL. Three patients had a mixed acinar and ductal carcinoma, 2 with a Gleason score (GS) of 8 and 1 with a GS of 7. Of the patients treated definitively, 4 had clinical stage T2A-T2C and 1 had clinical stage T1B. Definitive radiotherapy was delivered to the prostate with doses between 72 Gy and 78 Gy. Pelvic lymph nodes were treated in all patients. One patient was treated postradical prostatectomy to the prostate bed to a dose of 60 Gy. Adjuvant androgen deprivation was given in 5 of the patients. Two of the patients died from metastatic disease at 1.4 and 7.1 years after treatment. The remaining 4 patients remain alive between 3.2 and 4.8 years from treatment, with 3 patients biochemically without evidence of disease. No patients have developed a local recurrence. CONCLUSIONS. Ductal carcinoma of the prostate may be treated effectively with external beam radiotherapy. Aggressive management is indicated, even with low-volume metastatic disease.

KW - Ductal carcinoma

KW - Prosiate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=34248388414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248388414&partnerID=8YFLogxK

U2 - 10.1002/cncr.22644

DO - 10.1002/cncr.22644

M3 - Article

VL - 109

SP - 2011

EP - 2015

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -